A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-911 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Latest Information Update: 22 Aug 2022
Price :
$35 *
At a glance
- Drugs Ropanicant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suven Life Sciences
- 13 Aug 2022 Results from two clinical studies (NCT03155503 and NCT03551288) assessing safety, tolerability and pharmacokinetics of ropanicant after single and multiple ascending doses in healthy subjects published in the Clinical Drug Investigation
- 25 May 2018 Status changed from recruiting to completed.
- 25 May 2017 According to a Suven Life Sciences media release, the topline results from this study are expected in the quarter first quarter of 2018.